GRAIL, Inc. is a healthcare company that develops and offers blood-based cancer detection tests and related services. Its primary product, Galleri, is designed for cancer screening in people over 50 without symptoms, while it also provides diagnostic tools to help identify cancer in patients showing clinical signs of the disease. The company additionally supports clinical research programs and offers a precision oncology platform based on methylation analysis for applications such as disease risk assessment and monitoring for cancer recurrence.
1Y: 146.27 (+137.1%) · range 43.03–146.27
entry readiness 0 · NOT READY · exit proximity 100
Value area 58.04–82.95 · 1% of 119d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| trend-signal | 1.000 | Oct 5, 2026 |
| trader-sentiment | 0.926 | Sep 23, 2026 |
Not yet labeled — the study prices these as positions mature.